Qiagen Exceeds Q4 2025 Expectations with Strong Financial Performance
ByAinvest
Friday, Feb 6, 2026 8:45 am ET1min read
QGEN--
Qiagen N.V. reported Q4 2025 net sales of $540 million, a 1% increase at constant exchange rates, exceeding expectations. The company's growth pillars achieved combined sales of $1.49 billion, an 8% increase at CER. Qiagen completed a $500 million share repurchase in January 2026. The firm's sales are split almost evenly between life sciences and molecular diagnostics, with nearly 90% generated from consumables. Qiagen operates in the healthcare sector, with a market capitalization of approximately $10.6 billion.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet